Estudo comparativo entre estibogluconato de sódio BP 88R e antimonio de meglumina no tratamento da leishmaniose cutânea: eficácia e segurança

Saldanha, Ana Cristina R; Romero, Gustavo Adolfo Sierra; Merchan-Hamann, Edgar; Magalhäes, Albino Verçosa; Macedo, Vanize de Oliveira.
Rev. Soc. Bras. Med. Trop ; 32(4): 383-7, jul.-ago. 1999. tab
Artigo em Português | LILACS | ID: lil-242906

Documentos relacionados

  1. Anti-<i>Leishmania</i> compounds can be screened using <i>Leishmania</i> spp. expressing red fluorescence (<i>tdTomato</i>).
  2. Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by Leishmania braziliensis.
  3. Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns.
  4. Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
  5. A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.
  6. Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.
  7. American tegumentary leishmaniasis diagnosis using L. (V.) braziliensis fixed promastigotes: a comparative performance of serological tests and spontaneous cure identification.
  8. Cutaneous schistosomiasis and leishmaniasis coinfection: a case report.
  9. Consolidation of a Molecular Signature of Healing in Cutaneous Leishmaniasis Is Achieved during the First 10 Days of Treatment.
  10. In vitro characterization of Leishmania (Viannia) braziliensis isolates from patients with different responses to Glucantime(®) treatment from Northwest Paraná, Brazil.